Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 4
2016 1
2017 7
2018 8
2019 9
2020 10
2021 7
2022 8
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. van den Ende T, et al. Among authors: van laarhoven hwm, bijlsma mf. Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504550 Clinical Trial.
Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer.
Dings MPG, van der Zalm AP, Bootsma S, van Maanen TFJ, Waasdorp C, van den Ende T, Liu D, Bailey P, Koster J, Zwijnenburg DA, Spek CA, Klomp JPG, Oubrie A, Hooijer GKJ, Meijer SL, van Berge Henegouwen MI, Hulshof MC, Bergman J, Oyarce C, Medema JP, van Laarhoven HWM, Bijlsma MF. Dings MPG, et al. Among authors: van laarhoven hwm, bijlsma mf. Cell Rep Med. 2022 Nov 15;3(11):100802. doi: 10.1016/j.xcrm.2022.100802. Epub 2022 Nov 4. Cell Rep Med. 2022. PMID: 36334593 Free PMC article.
Genetic and non-genetic risk factors for early-onset pancreatic cancer.
Nodari Y, Gentiluomo M, Mohelnikova-Duchonova B, Kreivenaite E, Milanetto AC, Skieceviciene J, Landi S, Lawlor RT, Petrone MC, Arcidiacono PG, Lovecek M, Gazouli M, Bijlsma MF, Morelli L, Kiudelis V, Tacelli M, Zanette DL, Soucek P, Uzunoglu F, Kaaks R, Izbicki J, Boggi U, Pezzilli R, Mambrini A, Pasquali C, van Laarhoven HW, Katzke V, Cavestro GM, Sperti C, Loos M, Latiano A, Erőss B, Oliverius M, Johnson T, Basso D, Neoptolemos JP, Aoki MN, Greenhalf W, Vodicka P, Archibugi L, Vanella G, Lucchesi M, Talar-Wojnarowska R, Jamroziak K, Saeedi MA, van Eijck CHJ, Kupcinskas J, Hussein T, Puzzono M, Bunduc S, Götz M, Carrara S, Szentesi A, Tavano F, Moz S, Hegyi P, Luchini C, Capurso G, Perri F, Ermini S, Theodoropoulos G, Capretti G, Palmieri O, Ginocchi L, Furbetta N, Canzian F, Campa D. Nodari Y, et al. Among authors: van laarhoven hw, bijlsma mf. Dig Liver Dis. 2023 Oct;55(10):1417-1425. doi: 10.1016/j.dld.2023.02.023. Epub 2023 Mar 25. Dig Liver Dis. 2023. PMID: 36973108 Free article.
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
van den Ende T, Ezdoglian A, Baas LM, Bakker J, Lougheed SM, Harrasser M, Waasdorp C, van Berge Henegouwen MI, Hulshof MCCM, Haj Mohammad N, van Hillegersberg R, Mook S, van der Laken CJ, van Grieken NCT, Derks S, Bijlsma MF, van Laarhoven HWM, de Gruijl TD. van den Ende T, et al. Among authors: van laarhoven hwm, bijlsma mf. Oncoimmunology. 2023 Jul 17;12(1):2233403. doi: 10.1080/2162402X.2023.2233403. eCollection 2023. Oncoimmunology. 2023. PMID: 37470057 Free PMC article.
Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.
Dings MPG, Manoukian P, Waasdorp C, Quik JSE, Strijker M, Lodestijn SC, van Neerven SM, Moreno LF, de Oliveira RL, Bonsing BA, Bruno MJ, Busch OR, Doukas M, van Eijck CH, Mohammad NH, de Hingh IH, Molenaar QI, Besselink MG, Vermeulen L, Medema JP, van Laarhoven HWM, Bijlsma MF. Dings MPG, et al. Among authors: van laarhoven hwm, bijlsma mf. Int J Cancer. 2023 Feb 1;152(3):511-523. doi: 10.1002/ijc.34276. Epub 2022 Sep 19. Int J Cancer. 2023. PMID: 36069222 Free PMC article.
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. Creemers A, et al. Among authors: van laarhoven hwm, bijlsma mf. Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28801248 Review.
Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma.
van den Ende T, van der Pol Y, Creemers A, Moldovan N, Boers D, van Berge Henegouwen MI, Hulshof MC, Cillessen SA, van Grieken NC, Pegtel DM, Derks S, Bijlsma MF, Mouliere F, van Laarhoven HW. van den Ende T, et al. Among authors: van laarhoven hw, bijlsma mf. J Pathol. 2023 Nov;261(3):286-297. doi: 10.1002/path.6175. Epub 2023 Aug 24. J Pathol. 2023. PMID: 37615198
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.
van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. van Hilst J, et al. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):199-207. doi: 10.1016/S2468-1253(19)30004-4. Epub 2019 Jan 24. Lancet Gastroenterol Hepatol. 2019. PMID: 30685489 Clinical Trial.
59 results